- Panuveitis treatments, encompassing medications and surgical interventions, play a critical role in managing this severe and vision-threatening inflammatory eye condition, which affects all layers of the uveal tract and often requires long-term care and immune modulation
- The growing demand for panuveitis treatment is primarily fueled by the increasing global burden of autoimmune and infectious diseases, heightened awareness about early eye disease intervention, and advancements in biologics and immunosuppressive drug development
- North America dominates the global panuveitis treatment market, holding the largest revenue share of 38.7% in 2025, owing to a high prevalence of uveitis-related disorders, robust healthcare infrastructure, rapid adoption of advanced therapeutic options, and substantial R&D investments by pharmaceutical companies in the U.S. and Canada
- Asia-Pacific is expected to be the fastest-growing region in the panuveitis treatment market during the forecast period due to improving healthcare access, a growing geriatric population, and increasing incidence of infectious diseases contributing to intraocular inflammation
- The corticosteroids segment is expected to lead the panuveitis drug market with a market share of 41.3% in 2025, attributed to their widespread availability, rapid anti-inflammatory effects, and continued use as the first-line therapy in acute and chronic uveitis cases
